Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Debate: Will chemotherapy continue to be standard treatment for symptomatic...

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for) ( Dr Paul de Souza - University of Western Sydney, New South Wales, Australia )

Lecture: Clinical Perspectives: How far are we from personalising treatment for...

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

Lecture: Clinical Perspectives: How far are we from personalising treatment for prostate cancer patients? ( Dr Paul de Souza - University of Western Sydney, New South Wales, Australia )

Debate: Will chemotherapy continue to be standard treatment for symptomatic...

Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (against) ( Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany )

Vitamin D as a prevention against breast cancer

Dr Song Yao - Roswell Cancer Center Institute, New York, USA

Vitamin D as a prevention against breast cancer ( Dr Song Yao - Roswell Cancer Center Institute, New York, USA )

Idelalisib shows promising results in patients with double refractory indolent...

Dr Andrew Davies - Southampton General Hospital, Southampton, UK;

$Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma ( Dr Andrew Davies - Southampton General Hospital, Southampton, UK; )$

Rituximab versus idelalisib in refractory CLL

Prof John Gribben - Queen Mary University London, London, UK; Prof Peter...

$Rituximab versus idelalisib in refractory CLL ( Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University Hospital, Leeds, UK )$

New agents extend progression-free survival in double refractory myeloma

Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta...

$New agents extend progression-free survival in double refractory myeloma ( Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, USA )$

Aspirin analogues developed for anti-cancer effects on leukaemia

Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK

Aspirin analogues developed for anti-cancer effects on leukaemia ( Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK )

Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic...

Dr Valentin Goede - University of Cologne, Cologne, Germany

Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients ( Dr Valentin Goede - University of Cologne, Cologne, Germany )

WIN Symposium 2014: Breakthrough biomarker investigations and combination...

Dr John Mendelsohn, Dr Razelle Kurzrock, Dr Mace Rothenberg

WIN Symposium 2014: Breakthrough biomarker investigations and combination therapies ( Dr John Mendelsohn, Dr Razelle Kurzrock, Dr Mace Rothenberg )

Surgical strategies available for renal cell carcinoma with inferior vena cava...

Prof Christopher G. Wood - The University of Texas MD Anderson Cancer Center...

Surgical strategies available for renal cell carcinoma with inferior vena cava invasion ( Prof Christopher G. Wood - The University of Texas MD Anderson Cancer Center, Houston, USA )

Use of robotics in kidney cancer surgery

Dr Christophe Vaessen - Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Use of robotics in kidney cancer surgery ( Dr Christophe Vaessen - Groupe Hospitalier Pitié-Salpêtrière, Paris, France )

More from ecancer